JP2021515541A5 - - Google Patents
Info
- Publication number
- JP2021515541A5 JP2021515541A5 JP2020542228A JP2020542228A JP2021515541A5 JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5 JP 2020542228 A JP2020542228 A JP 2020542228A JP 2020542228 A JP2020542228 A JP 2020542228A JP 2021515541 A5 JP2021515541 A5 JP 2021515541A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1803746.5 | 2018-03-08 | ||
| GBGB1803746.5A GB201803746D0 (en) | 2018-03-08 | 2018-03-08 | PD1 binding agents |
| GBGB1813405.6A GB201813405D0 (en) | 2018-03-08 | 2018-08-16 | PD1 binding agents |
| GB1813405.6 | 2018-08-16 | ||
| PCT/EP2019/055927 WO2019170898A1 (en) | 2018-03-08 | 2019-03-08 | Pd1 binding agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515541A JP2021515541A (ja) | 2021-06-24 |
| JP2021515541A5 true JP2021515541A5 (enExample) | 2022-03-15 |
Family
ID=61972796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542228A Pending JP2021515541A (ja) | 2018-03-08 | 2019-03-08 | Ｐｄ１結合剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10858435B2 (enExample) |
| EP (1) | EP3762419A1 (enExample) |
| JP (1) | JP2021515541A (enExample) |
| CN (1) | CN111819199A (enExample) |
| AU (1) | AU2019229676A1 (enExample) |
| CA (1) | CA3092174A1 (enExample) |
| GB (2) | GB201803746D0 (enExample) |
| IL (1) | IL277135A (enExample) |
| SG (1) | SG11202008246VA (enExample) |
| WO (1) | WO2019170898A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| WO2021076197A1 (en) * | 2019-10-15 | 2021-04-22 | Diverse Biotech, Inc. | Conjugate molecules |
| CR20220596A (es) | 2020-05-26 | 2023-01-23 | Boehringer Ingelheim Int | Anticuerpos anti-pd-1 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2017055404A1 (en) * | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
-
2018
- 2018-03-08 GB GBGB1803746.5A patent/GB201803746D0/en not_active Ceased
- 2018-08-16 GB GBGB1813405.6A patent/GB201813405D0/en not_active Ceased
-
2019
- 2019-03-08 AU AU2019229676A patent/AU2019229676A1/en not_active Abandoned
- 2019-03-08 CN CN201980017416.5A patent/CN111819199A/zh active Pending
- 2019-03-08 WO PCT/EP2019/055927 patent/WO2019170898A1/en not_active Ceased
- 2019-03-08 JP JP2020542228A patent/JP2021515541A/ja active Pending
- 2019-03-08 EP EP19710389.8A patent/EP3762419A1/en not_active Withdrawn
- 2019-03-08 SG SG11202008246VA patent/SG11202008246VA/en unknown
- 2019-03-08 CA CA3092174A patent/CA3092174A1/en active Pending
-
2020
- 2020-06-25 US US16/912,023 patent/US10858435B2/en not_active Expired - Fee Related
- 2020-09-03 IL IL277135A patent/IL277135A/en unknown
- 2020-11-19 US US16/952,678 patent/US20210101981A1/en not_active Abandoned